Cancer / Immunology
Pfizer And Astellas Report Strong Phase III EV 304 Results For PADCEV Plus Pembrolizumab In MIBC
In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with ove...
March 02, 2026 | News
Optellum Secures TGA Approval In Australia For AI Powered Virtual Nodule Clinic
Optellum, the leading AI-enabled solution for earlier lung cancer detection, is thrilled to announce that it has received Therapeutic Goods Administration ...
March 02, 2026 | News
WuXi XDC And Earendil Labs Forge Strategic Alliance To Advance Next Generation AI Designed ADCs
WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializin...
March 02, 2026 | News
Astellas And Vir Biotechnology Forge Global Partnership To Advance VIR 5500 In Prostate Cancer
- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commerci...
February 25, 2026 | News
AVEO Oncology Selects Ficlatuzumab Dose for Phase 3 FIERCE-HN Trial in Head and Neck Cancer
– Global enrollment continues in the Phase 3 registrational studyfollowing the planned first interim analysis for patients with HPV-negati...
February 24, 2026 | News
ImmunityBio Partners With Accord Healthcare To Expand ANKTIVA Access Across Europe
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, announced a partnership with Accord Healthcare to provide access to ANKTI...
February 23, 2026 | News
ANKTIVA Plus BCG Secures European Commission Authorization As First Immunotherapy For BCG Unresponsive NMIBC
ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive blad...
February 20, 2026 | News
Telix Submits European Marketing Application For TLX101 Px To Expand Glioma PET Imaging Access
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has submitted a marketing authorization application (MAA) in Europe ...
February 19, 2026 | News
Bio Techne Corporation Announces CE IVD Marking For Ella Benchtop Immunoassay Platform In European Union
Ella benchtop instrument is now CE-IVD marked and available for sale in the EU Enables diagnostic assay developers to leverage a simplified platform tha...
February 18, 2026 | News
Eli Lilly And Company Reports Statistically Significant Event Free Survival Benefit With Selpercatinib In Early Stage RET Fusion Positive NSCLC
Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or deat...
February 18, 2026 | News
Innovent Advances IBI354 Into Pivotal Phase Three Trial For HER2 Positive Advanced Breast Cancer
Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medi...
February 16, 2026 | News
Jyong Biotech Strengthens Preventive Medicine Position With Positive Phase II Data And Asian Expansion
Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modul...
February 16, 2026 | News
HanchorBio Secures FDA Orphan Drug Designation For HCB101 In Gastric Cancer
First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnolog...
February 16, 2026 | News
Alphamab Oncology Advances JSKN003 Into Phase III Trial For HER2 Positive Advanced Colorectal Cancer
Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005...
February 16, 2026 | News
Most Read
- How Does GLP-1 Work?
- Innovations In Magnetic Resonance Imaging Introduced By United Imaging
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
